Literature DB >> 9192662

Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM.

P M Lavoie1, J Thibodeau, I Cloutier, R Busch, R P Sékaly.   

Abstract

Bacterial superantigens (SAgs) bind to major histocompatibility complex (MHC) class II molecules and activate T cells in a Vbeta-restricted fashion. We recently identified subsets of HLA-DR1 molecules that show selectivity for SAgs. Here, we extend these observations by showing that different cell lineages demonstrate distinct SAg-binding specificities although they all express HLA-DR1. Indeed, B cells bind staphylococcal enterotoxin A (SEA) and toxic shock syndrome toxin 1 (TSST-1) with high affinity while staphylococcal enterotoxin B (SEB) binding is barely detectable. In contrast, DR1-transfected HeLa cells show efficient binding of SEB, but not of SEA or TSST-1. We investigated the class II maturation events required for efficient interaction with SAgs and found that the ability of cells to bind and present the toxins can be drastically modulated by coexpression of the class II-associated invariant chain (Ii) and HLA-DM. SEA binding to DR1 molecules required coexpression of Ii, whereas TSST-1 binding was selectively enhanced by DM. Binding of SEB was affected by cell type-specific factors other than Ii or DM. The selectivity of SAgs for different MHC class II populations was minimally affected by HLA-DR intrinsic polymorphism and could not be explained by binding to alternative sites on DR molecules. Our results indicate that SAgs are sensitive to structural heterogeneity in class II molecules, which is consequent to the differential regulation of expression of antigen processing cofactors. Therefore, we speculate that Staphylococcus aureus have retained the ability to express numerous SAgs in adaptation to the micro-heterogeneity displayed by MHC class II molecules and that this may relate to their ability to infect different tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192662      PMCID: PMC21255          DOI: 10.1073/pnas.94.13.6892

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.

Authors:  R M Chicz; R G Urban; W S Lane; J C Gorga; L J Stern; D A Vignali; J L Strominger
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

2.  Staphylococcal toxins bind to different sites on HLA-DR.

Authors:  M M Chintagumpala; J A Mollick; R R Rich
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

3.  Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype.

Authors:  J A Mollick; M Chintagumpala; R G Cook; R R Rich
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

4.  Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes.

Authors:  E Mellins; L Smith; B Arp; T Cotner; E Celis; D Pious
Journal:  Nature       Date:  1990-01-04       Impact factor: 49.962

5.  Synthesis and expression of MHC class II molecules in the absence of attached invariant chains by recombinant-interferon-gamma-activated bone-marrow-derived macrophages.

Authors:  F J Schneider; B Opel; W Ballhausen; W Henkes; P Steinlein; K Reske
Journal:  Eur J Immunol       Date:  1987-09       Impact factor: 5.532

6.  HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells.

Authors:  S Jacobson; R P Sekaly; C L Jacobson; H F McFarland; E O Long
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

7.  Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells.

Authors:  E O Long; S Rosen-Bronson; D R Karp; M Malnati; R P Sekaly; D Jaraquemada
Journal:  Hum Immunol       Date:  1991-08       Impact factor: 2.850

8.  Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen.

Authors:  T S Jardetzky; J H Brown; J C Gorga; L J Stern; R G Urban; Y I Chi; C Stauffacher; J L Strominger; D C Wiley
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

9.  Distribution and expression of toxic shock syndrome toxin 1 gene among Staphylococcus aureus isolates of toxic shock syndrome and non-toxic shock syndrome origin.

Authors:  P F Bonventre; L Weckbach; G Harth; C Haidaris
Journal:  Rev Infect Dis       Date:  1989 Jan-Feb

10.  Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR.

Authors:  A Herman; N Labrecque; J Thibodeau; P Marrack; J W Kappler; R P Sekaly
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

View more
  4 in total

Review 1.  HLA-DM and the MHC class II antigen presentation pathway.

Authors:  P E Jensen; D A Weber; W P Thayer; X Chen; C T Dao
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Polymorphisms in HLA Class II Genes Are Associated With Susceptibility to Staphylococcus aureus Infection in a White Population.

Authors:  Gerald N DeLorenze; Charlotte L Nelson; William K Scott; Andrew S Allen; G Thomas Ray; Ai-Lin Tsai; Charles P Quesenberry; Vance G Fowler
Journal:  J Infect Dis       Date:  2015-10-08       Impact factor: 5.226

3.  Superantigen-presentation by rat major histocompatibility complex class II molecules RT1.Bl and RT1.Dl.

Authors:  Henry Dlaske; Hatice Karaüzüm; Elisa Monzon-Casanova; Ronald Rudolf; Lisa Starick; Ingrid Müller; Gerhild Wildner; Maria Diedrichs-Möhring; Norbert Koch; Tohru Miyoshi-Akiyama; Takehiko Uchiyama; Kurt Wonigeit; Bernhard Fleischer; Silke Overbeck; Lothar Rink; Thomas Herrmann
Journal:  Immunology       Date:  2008-12-24       Impact factor: 7.397

4.  Evaluating genetic susceptibility to Staphylococcus aureus bacteremia in African Americans using admixture mapping.

Authors:  D D Cyr; A S Allen; G-J Du; F Ruffin; C Adams; J T Thaden; S A Maskarinec; M Souli; S Guo; D M Dykxhoorn; W K Scott; V G Fowler
Journal:  Genes Immun       Date:  2017-03-23       Impact factor: 2.676

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.